A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 117 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one has the largest enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 5th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 566 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, Inc., a Bristol Myers Squibb company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 3, and was the 6th registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) for up to 52 weeks. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and characterize the pharmacokinetics of xanomeline and trospium after administration of KarXT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is capable of providing .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline and Trospium Chloride Capsules
Drug pages: Xanomeline · Trospium chloride
Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Also known as: KarXT
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Serious Treatment Emergent Adverse Events (STEAEs)
An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With TEAE Leading to Study Drug Discontinuation
TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in PANSS Total Score at Week 52
The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.
Time frame: At baseline and week 52
Change From Baseline in PANSS Positive Score at Week 52
PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility.
Time frame: At baseline and week 52
Change From Baseline in PANSS Negative Score at Week 52
PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions.
Time frame: At baseline and week 52
Change From Baseline in PANSS Marder Factor Negative Score at Week 52
PANSS Marder factor score is a subscale of the PANSS; the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom subscale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions.
Time frame: At baseline and week 52
Change From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52
Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.
Time frame: At baseline and week 52
Percentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 52
A PANSS responder is defined as a participant with a reduction from baseline of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.
Time frame: At baseline and week 52
Number of Participants With Adverse Events of Special Interest (AESI)
LFT elevations, inclusive of drug-induced liver injury (DILI) and symptomatic orthostasis including syncope (a transient loss of consciousness or fainting) is to be captured as an AESI and reported as such. Non symptomatic orthostasis will not be reported as an AESI. Any such AESI due to any cause, whether or not related to KarXT, must be reported within 24 hours of occurrence or when the investigator becomes aware of the event.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Anticholinergic and Procholinergic Symptoms
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Simpson-Angus Rating Scale (SAS)
The Simpson-Angus Rating Scale (SAS) is a clinical tool used to assess the severity of extrapyramidal symptoms (EPS), which are drug-induced movement disorders often associated with antipsychotic medications. The scale consists of 10 items, each rated from 0 (none) to 4 (severe), with a total score range of 0 to 40. Higher scores indicate more severe symptoms. The SAS helps clinicians monitor and manage EPS in patients, guiding treatment decisions to minimize these side effects.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS)
The Abnormal Involuntary Movement Scale (AIMS) is a tool used to assess the severity of tardive dyskinesia and other involuntary movements, often caused by antipsychotic medications. It includes 12 items, with the first 10 focusing on specific body areas and movement severity, rated from 0 (none) to 4 (severe). The total score ranges from 0 to 28, with higher scores indicating more severe symptoms. AIMS helps clinicians monitor and manage these movement disorders, guiding treatment adjustments to reduce side effects.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Body Mass Index (BMI)
BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Waist Circumference
The change in waist circumference in centimeters from baseline. Baseline is defined as measurements taken at screening.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Blood Pressure Values
The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
Time frame: From time of consent to end of study (approximately 400 days)
Change From Baseline in Heart Rate
The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Laboratory assessments include: * Hematology * Serum chemistry * Urinalysis * HbA1c * Prolactin levels * Coagulation studies * Viral Serology * Pregnancy test
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram
An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Clinically Significant Changes in Physical Examination
A complete physical examination (body temperature, general appearance, head/eyes/ears/nose/throat \[HEENT\], examination of thorax and abdomen, assessment of cardiac, musculoskeletal, and circulatory systems, palpations for lymphadenopathy, and limited neurological examination) will be performed. A targeted physical examination includes at a minimum body temperature, a check of general appearance, as well as examination of organ systems that are relevant to the investigator based on review of the participant's reported AEs, review of systems, or concomitant medication use. These also include symptom-driven physical examinations which will be performed as clinically indicated at any study visit.
Time frame: From time of consent to end of study (approximately 400 days)
Number of Participants With Suicidal Ideation Based on the Columbia Suicide Severity Rating Scale (C-SSRS)
The Columbia Suicide Severity Rating Scale (C-SSRS) is a tool used to assess the severity and immediacy of suicidal ideation and behavior. It covers suicidal thoughts, plans, and actions, including the frequency, intensity, and context of these behaviors. The C-SSRS does not use a numerical scoring system like some other assessment tools. Instead, it categorizes the severity of suicidal ideation and behavior based on specific criteria. The scale helps clinicians identify individuals at risk of suicide and monitor changes over time, guiding treatment decisions and ensuring safety. It is quick and easy to administer, making it useful in various clinical and research settings.
Time frame: From time of consent to end of study (approximately 400 days)
| Milestone | KarXT |
|---|---|
| Started | 566 |
| Completed | 277 |
| Not completed | 289 |
| Withdrew: Adverse event | 96 |
| Withdrew: Ineligible for further treatment according to inclusion/exclusion criteria | 1 |
| Withdrew: Consent withdrawn | 93 |
| Withdrew: Failure to adhere to protocol | 32 |
| Withdrew: Alcohol or drug use | 6 |
| Withdrew: Lost to follow-up | 46 |
| Withdrew: Death | 2 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Other reasons | 12 |
TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
| Participants | KarXT |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 466 |
An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
| Participants | KarXT |
|---|---|
| Number of Participants With Serious Treatment Emergent Adverse Events (STEAEs) | 41 |
TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
| Participants | KarXT |
|---|---|
| Number of Participants With TEAE Leading to Study Drug Discontinuation | 100 |
The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in PANSS Total Score at Week 52 | -5.5 ± 11.11 |
PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in PANSS Positive Score at Week 52 | -1.9 ± 3.71 |
PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in PANSS Negative Score at Week 52 | -0.8 ± 4.42 |
PANSS Marder factor score is a subscale of the PANSS; the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom subscale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in PANSS Marder Factor Negative Score at Week 52 | -1.1 ± 4.49 |
Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52 | -0.4 ± 0.70 |
A PANSS responder is defined as a participant with a reduction from baseline of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.
| percentage of participants | KarXT |
|---|---|
| Percentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 52 | 9.2 |
LFT elevations, inclusive of drug-induced liver injury (DILI) and symptomatic orthostasis including syncope (a transient loss of consciousness or fainting) is to be captured as an AESI and reported as such. Non symptomatic orthostasis will not be reported as an AESI. Any such AESI due to any cause, whether or not related to KarXT, must be reported within 24 hours of occurrence or when the investigator becomes aware of the event.
| Participants | KarXT |
|---|---|
| Number of Participants With Adverse Events of Special Interest (AESI) | 19 |
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
| Participants | KarXT |
|---|---|
| Anticholinergic | 159 |
| Procholinergic | 210 |
The Simpson-Angus Rating Scale (SAS) is a clinical tool used to assess the severity of extrapyramidal symptoms (EPS), which are drug-induced movement disorders often associated with antipsychotic medications. The scale consists of 10 items, each rated from 0 (none) to 4 (severe), with a total score range of 0 to 40. Higher scores indicate more severe symptoms. The SAS helps clinicians monitor and manage EPS in patients, guiding treatment decisions to minimize these side effects.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in Simpson-Angus Rating Scale (SAS) | 0.1 ± 0.48 |
The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in Barnes Akathisia Rating Scale (BARS) | 0.1 ± 0.58 |
The Abnormal Involuntary Movement Scale (AIMS) is a tool used to assess the severity of tardive dyskinesia and other involuntary movements, often caused by antipsychotic medications. It includes 12 items, with the first 10 focusing on specific body areas and movement severity, rated from 0 (none) to 4 (severe). The total score ranges from 0 to 28, with higher scores indicating more severe symptoms. AIMS helps clinicians monitor and manage these movement disorders, guiding treatment adjustments to reduce side effects.
| Score on a Scale | KarXT |
|---|---|
| Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) | 0.1 ± 0.57 |
BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.
| kg/m^2 | KarXT |
|---|---|
| Change From Baseline in Body Mass Index (BMI) | -0.761 ± 2.0108 |
The change in waist circumference in centimeters from baseline. Baseline is defined as measurements taken at screening.
| cm | KarXT |
|---|---|
| Change From Baseline in Waist Circumference | -1.549 ± 7.3558 |
The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
| mmHG | KarXT |
|---|---|
| Supine Systolic | 0.1 ± 12.83 |
| Standing Systolic | -0.7 ± 12.33 |
| Supine Diastolic | 0.1 ± 8.72 |
| Standing Diastolic | -0.2 ± 8.26 |
The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
| beats/min | KarXT |
|---|---|
| Supine Heart Rate | 0.7 ± 11.43 |
| Standing Heart Rate | 0.1 ± 11.22 |
Laboratory assessments include: * Hematology * Serum chemistry * Urinalysis * HbA1c * Prolactin levels * Coagulation studies * Viral Serology * Pregnancy test
| Participants | KarXT |
|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 |
An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.
| Participants | KarXT |
|---|---|
| Number of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram | 0 |
A complete physical examination (body temperature, general appearance, head/eyes/ears/nose/throat \[HEENT\], examination of thorax and abdomen, assessment of cardiac, musculoskeletal, and circulatory systems, palpations for lymphadenopathy, and limited neurological examination) will be performed. A targeted physical examination includes at a minimum body temperature, a check of general appearance, as well as examination of organ systems that are relevant to the investigator based on review of the participant's reported AEs, review of systems, or concomitant medication use. These also include symptom-driven physical examinations which will be performed as clinically indicated at any study visit.
| Participants | KarXT |
|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examination | 3 |
The Columbia Suicide Severity Rating Scale (C-SSRS) is a tool used to assess the severity and immediacy of suicidal ideation and behavior. It covers suicidal thoughts, plans, and actions, including the frequency, intensity, and context of these behaviors. The C-SSRS does not use a numerical scoring system like some other assessment tools. Instead, it categorizes the severity of suicidal ideation and behavior based on specific criteria. The scale helps clinicians identify individuals at risk of suicide and monitor changes over time, guiding treatment decisions and ensuring safety. It is quick and easy to administer, making it useful in various clinical and research settings.
| Participants | KarXT |
|---|---|
| Wish to be dead | 1 |
| Non-Specific Active Suicidal Thoughts | 1 |
| Active Suicidal Ideation with any methods without intent to act | 0 |
| Active Suicidal Ideation with some intent to act but without a plan | 1 |
| Active Suicidal Ideation with specific plan and intent | 0 |
Collected over From time of consent to end of study (approximately 400 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KarXT | 2/566 (0.4%) | 41/566 (7.2%) | 356/566 (62.9%) |
| Event | KarXT |
|---|---|
| SchizophreniaPsychiatric disorders | 10/566 |
| Psychotic disorderPsychiatric disorders | 4/566 |
| Abdominal painGastrointestinal disorders | 2/566 |
| VomitingGastrointestinal disorders | 2/566 |
| DeathGeneral disorders | 2/566 |
| DizzinessNervous system disorders | 2/566 |
| Angina pectorisCardiac disorders | 1/566 |
| DiarrhoeaGastrointestinal disorders | 1/566 |
| DyspepsiaGastrointestinal disorders | 1/566 |
| COVID-19Infections and infestations | 1/566 |
| Event | KarXT |
|---|---|
| NauseaGastrointestinal disorders | 131/566 |
| VomitingGastrointestinal disorders | 113/566 |
| ConstipationGastrointestinal disorders | 102/566 |
| HypertensionVascular disorders | 59/566 |
| Dry mouthGastrointestinal disorders | 53/566 |
| DiarrhoeaGastrointestinal disorders | 52/566 |
| DizzinessNervous system disorders | 49/566 |
| HeadacheNervous system disorders | 46/566 |
| DyspepsiaGastrointestinal disorders | 41/566 |
| SomnolenceNervous system disorders | 35/566 |
| Age, Continuous(Years) | KarXT |
|---|---|
| Mean | 47.4 ± 11.76 |
| Sex: Female, Male(Participants) | KarXT |
|---|---|
| Female | 191 |
| Male | 375 |
| Ethnicity (NIH/OMB)(Participants) | KarXT |
|---|---|
| Hispanic or Latino | 119 |
| Not Hispanic or Latino | 443 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | KarXT |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 389 |
| White | 164 |
| More than one race | 0 |
| Unknown or Not Reported | 5 |
Showing the first 100 of 117 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in May 2024, 35 months.
Results were first posted in Sep 2025, 1 year 3 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 35 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →